Skip to main content
. 2021 Aug 30;46(5):636–645. doi: 10.1016/j.jgr.2021.08.004

Fig. 6.

Fig. 6

TSPYL2 overexpression sensitizes PAAD cells to gemcitabine. A-B. Gemcitabine IC50 of PANC-1 (A) and BxPC-3 (B) cells with or without TSPYL2 overexpression. C-E. PANC-1 and BxPC-3 cells with or without TSPYL2 overexpression were treated with 20 or 10 nM gemcitabine for 48 h respectively. Then cells were then harvested, stained by Annexin/PI, and analyzed by flow cytometry. Representative flow cytometric images (C) were shown and the percentage of apoptotic cells (means ± SD) (D–E) were calculated. F. Bax, Bcl-2, cleaved caspase-3 and γ-H2AX protein expression in PANC-1 and BxPC-3 cells after the treatment as indicated in panel C. G. Gemcitabine IC50 of PANC-1/GR cells with or without TSPYL2 overexpression. H–I. PANC-1/GR cells with or without TSPYL2 overexpression were treated with 100 nM gemcitabine for 48 h. Flow cytometric analysis was conducted for Annexin/PI staining. Representative flow cytometric images (H) were shown and the percentage of apoptotic cells (means ± SD) (I) were calculated. J-K. PANC-1/GR cells after the treatment as indicated in panel H were subjected to IF staining of γ-H2AX foci formation. Representative image (J) and quantitation (K) of γ-H2AX foci formation were shown. P < 0.001. Scale bar: 20 μm.